You are here

Bluebird, Celgene myeloma therapy improves with time, study finds

CAR-T treatment removes patient's own immune system cells and tweaking them to attack the cancer

Minneapolis

A novel therapy from Bluebird Bio Inc and Celgene Corp for patients nearing death from an aggressive form of blood cancer appears to get more effective over time, wiping out signs of disease in more than half of those treated in a small trial.

A single infusion of the...

sentifi.com

Market voices on: